BACKGROUND: Insulin/insulin-like growth factor-I (IGF-I) signaling is a mechanism mediating the promoting effect of type 2 diabetes (DM2) on cancer. Human epidermal growth factor receptor (HER2), insulin receptor and IGF-I receptor involve the same PI3K/AKT/mTOR signaling, and different antidiabetic pharmacotherapy may differentially affect this pathway, leading to different prognoses of HER2+ breast cancer. METHODS: We reviewed 1983 consecutive patients with HER2+ breast cancer treated between 1 January 1998 and 30 September 2010. The overall survival, breast cancer-specific death rate, age, race, nuclear grade, stage, menopausal status, estrogen and progesterone receptor status, body mass index and classes of antidiabetic pharmacotherapy were analyzed. RESULTS: A Cox regression analysis showed that DM2 [P=0.026, hazard ratio (HR)=1.42, 95 % confidence interval (95 % CI) 1.04-1.94] predicted poor survival of stage≥2 HER2+ breast cancer. In Kaplan-Meier analysis, metformin predicted lengthened survival and so did thiazolidinediones. Analyzing only the diabetics, Cox regression showed that metformin (P=0.041, HR=0.52, 95 % CI 0.28-0.97) and thiazolidinediones (P=0.036; HR=0.41, 95% CI 0.18-0.93) predicted lengthened survival, and competing risk analysis showed that metformin and thiazolidinediones were associated with decreased breast cancer-specific mortality (P=0.023, HR=0.47, 95% CI 0.24-0.90 and P=0.044, HR=0.42, 95 % CI 0.18-0.98, respectively). CONCLUSIONS: Thiazolidinediones and metformin users are associated with better clinical outcomes than nonusers in diabetics with stage≥2 HER2+ breast cancer. The choice of antidiabetic pharmacotherapy may influence prognosis of this group.
BACKGROUND:Insulin/insulin-like growth factor-I (IGF-I) signaling is a mechanism mediating the promoting effect of type 2 diabetes (DM2) on cancer. Humanepidermal growth factor receptor (HER2), insulin receptor and IGF-I receptor involve the same PI3K/AKT/mTOR signaling, and different antidiabetic pharmacotherapy may differentially affect this pathway, leading to different prognoses of HER2+ breast cancer. METHODS: We reviewed 1983 consecutive patients with HER2+ breast cancer treated between 1 January 1998 and 30 September 2010. The overall survival, breast cancer-specific death rate, age, race, nuclear grade, stage, menopausal status, estrogen and progesterone receptor status, body mass index and classes of antidiabetic pharmacotherapy were analyzed. RESULTS: A Cox regression analysis showed that DM2 [P=0.026, hazard ratio (HR)=1.42, 95 % confidence interval (95 % CI) 1.04-1.94] predicted poor survival of stage≥2 HER2+ breast cancer. In Kaplan-Meier analysis, metformin predicted lengthened survival and so did thiazolidinediones. Analyzing only the diabetics, Cox regression showed that metformin (P=0.041, HR=0.52, 95 % CI 0.28-0.97) and thiazolidinediones (P=0.036; HR=0.41, 95% CI 0.18-0.93) predicted lengthened survival, and competing risk analysis showed that metformin and thiazolidinediones were associated with decreased breast cancer-specific mortality (P=0.023, HR=0.47, 95% CI 0.24-0.90 and P=0.044, HR=0.42, 95 % CI 0.18-0.98, respectively). CONCLUSIONS:Thiazolidinediones and metformin users are associated with better clinical outcomes than nonusers in diabetics with stage≥2 HER2+ breast cancer. The choice of antidiabetic pharmacotherapy may influence prognosis of this group.
Authors: John R Benson; Ismail Jatoi; Martin Keisch; Francisco J Esteva; Andreas Makris; V Craig Jordan Journal: Lancet Date: 2009-04-25 Impact factor: 79.321
Authors: Kimberly S Peairs; Bethany B Barone; Claire F Snyder; Hsin-Chieh Yeh; Kelly B Stein; Rachel L Derr; Frederick L Brancati; Antonio C Wolff Journal: J Clin Oncol Date: 2010-11-29 Impact factor: 44.544
Authors: Pamela J Goodwin; Kathleen I Pritchard; Marguerite Ennis; Mark Clemons; Margaret Graham; I George Fantus Journal: Clin Breast Cancer Date: 2008-12 Impact factor: 3.225
Authors: William A Stokes; Megan Eguchi; Arya Amini; Mohammad K Hararah; Ding Ding; Jessica D McDermott; Cathy J Bradley; Sana D Karam Journal: Oral Oncol Date: 2018-06-30 Impact factor: 5.337
Authors: Sara Gandini; Matteo Puntoni; Brandy M Heckman-Stoddard; Barbara K Dunn; Leslie Ford; Andrea DeCensi; Eva Szabo Journal: Cancer Prev Res (Phila) Date: 2014-07-01
Authors: Dan Y Gui; Lucas B Sullivan; Alba Luengo; Aaron M Hosios; Lauren N Bush; Nadege Gitego; Shawn M Davidson; Elizaveta Freinkman; Craig J Thomas; Matthew G Vander Heiden Journal: Cell Metab Date: 2016-10-13 Impact factor: 27.287
Authors: Brandy M Heckman-Stoddard; Sara Gandini; Matteo Puntoni; Barbara K Dunn; Andrea DeCensi; Eva Szabo Journal: Semin Oncol Date: 2015-09-08 Impact factor: 4.929
Authors: Daniel E Spratt; Chi Zhang; Zachary S Zumsteg; Xin Pei; Zhigang Zhang; Michael J Zelefsky Journal: Eur Urol Date: 2012-12-14 Impact factor: 20.096